HK1198359A1 - Carrier-linked treprostinil prodrugs - Google Patents

Carrier-linked treprostinil prodrugs Download PDF

Info

Publication number
HK1198359A1
HK1198359A1 HK14111870.6A HK14111870A HK1198359A1 HK 1198359 A1 HK1198359 A1 HK 1198359A1 HK 14111870 A HK14111870 A HK 14111870A HK 1198359 A1 HK1198359 A1 HK 1198359A1
Authority
HK
Hong Kong
Prior art keywords
carrier
linked treprostinil
prodrugs
treprostinil prodrugs
treprostinil
Prior art date
Application number
HK14111870.6A
Other languages
English (en)
Chinese (zh)
Inventor
Ulrich Hersel
Harald Rau
Torben Lessmann
Nicola BISEK
Guillaume Maitro
Kennett Sprogøe
Thomas Wegge
Joachim Zettler
Oliver Keil
Original Assignee
Ascendis Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma A/S filed Critical Ascendis Pharma A/S
Publication of HK1198359A1 publication Critical patent/HK1198359A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14111870.6A 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs HK1198359A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11177409 2011-08-12
EP11177409 2011-08-12
EP11195615 2011-12-23
EP11195615 2011-12-23
EP12165508 2012-04-25
EP12165508 2012-04-25
PCT/EP2012/065745 WO2013024052A1 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Publications (1)

Publication Number Publication Date
HK1198359A1 true HK1198359A1 (en) 2015-04-10

Family

ID=46690494

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111870.6A HK1198359A1 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Country Status (14)

Country Link
US (2) US9561287B2 (OSRAM)
EP (1) EP2741781A1 (OSRAM)
JP (1) JP6092867B2 (OSRAM)
KR (1) KR101997939B1 (OSRAM)
CN (1) CN103857413A (OSRAM)
AU (1) AU2012296954B2 (OSRAM)
BR (1) BR112014003225A2 (OSRAM)
CA (1) CA2843883C (OSRAM)
HK (1) HK1198359A1 (OSRAM)
IL (1) IL230712A (OSRAM)
IN (1) IN2014CN00989A (OSRAM)
MX (1) MX349950B (OSRAM)
WO (1) WO2013024052A1 (OSRAM)
ZA (1) ZA201400977B (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296954B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
HK1205697A1 (zh) * 2012-04-25 2015-12-24 Ascendis Pharma A/S 含有羟基的药物的前药
AU2013353985B2 (en) 2012-12-07 2017-07-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014160638A1 (en) * 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
US9758465B2 (en) 2013-04-30 2017-09-12 United Therapeutics Corporation Controlled release pharmaceutical formulations
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
CA2952223C (en) * 2014-06-13 2023-08-01 United Therapeutics Corporation Treprostinil formulations
WO2016010538A1 (en) * 2014-07-16 2016-01-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
EP3226838A1 (en) 2014-12-03 2017-10-11 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
US9643911B2 (en) * 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11311604B2 (en) 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
EP4162955A1 (en) 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
WO2017118703A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
KR102786270B1 (ko) 2016-03-01 2025-03-24 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
IL265270B (en) * 2016-09-15 2022-09-01 Camurus Ab Prostacyclin analog formulations
CA3037444A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
KR20230170810A (ko) 2016-09-29 2023-12-19 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
BR112019005351A2 (pt) 2016-09-29 2019-06-11 Ascendis Pharma Growth Disorders As terapia combinada com agonistas de cnp de liberação controlada
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
PT3793587T (pt) 2018-05-18 2025-07-25 Ascendis Pharma Bone Diseases As Dose inicial de conjugados de pth
US20210338834A1 (en) 2018-09-26 2021-11-04 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
US20210330798A1 (en) 2018-09-26 2021-10-28 Ascendis Pharma A/S Treatment of infections
US20210330807A1 (en) 2018-09-26 2021-10-28 Ascendis Pharma A/S Novel hydrogel conjugates
EP3906032A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
MX2021007706A (es) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Conjugados de agonistas de receptor de reconocimiento de patron.
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
BR112021014581A2 (pt) 2019-02-11 2021-12-14 Ascendis Pharma Bone Diseases As Formulações farmacêuticas líquidas de conjugados de pth
WO2020165081A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
WO2020254609A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254611A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
IL294357A (en) 2020-01-13 2022-08-01 Ascendis Pharma Bone Diseases As Hypoparathyroidism treatment
US20230241217A1 (en) 2020-05-04 2023-08-03 Ascendis Pharma A/S Hydrogel irradiation
US11793780B2 (en) * 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
MX2023003540A (es) 2020-09-28 2023-04-21 Ascendis Pharma Bone Diseases As Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
TW202246206A (zh) * 2021-03-16 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種曲前列環素衍生物及其用途
IL311539A (en) 2021-09-22 2024-05-01 Ascendis Pharma Bone Diseases As Long-acting pth compound treatments
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CA3238942A1 (en) 2021-12-13 2023-06-22 Vibeke MILLER BREINHOLT Cancer treatments with tlr7/8 agonists
CN116444377A (zh) * 2022-01-07 2023-07-18 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途
US20250195617A1 (en) 2022-05-23 2025-06-19 Ascendis Pharma Growth Disorders A/S Liquid Pharmaceutical Formulations of CNP Compounds
CN120752051A (zh) 2022-11-02 2025-10-03 阿森迪斯药物骨疾病股份有限公司 包含两种pth化合物的pth治疗方案
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
WO2000057701A1 (en) 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
ES2331187T3 (es) * 2003-12-16 2009-12-23 United Therapeutics Corporation Utilizacion de treprostinil para mejorar las funciones renales.
EP1625856A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US20080280986A1 (en) 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
ES2362386T3 (es) * 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
PT3050576T (pt) 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
MX2011003117A (es) * 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
BR112012002280B1 (pt) * 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
AU2012296954B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs

Also Published As

Publication number Publication date
IL230712A (en) 2017-08-31
KR101997939B1 (ko) 2019-07-08
KR20140070545A (ko) 2014-06-10
BR112014003225A2 (pt) 2017-03-01
AU2012296954B2 (en) 2016-09-15
WO2013024052A1 (en) 2013-02-21
JP2014527050A (ja) 2014-10-09
MX2014001497A (es) 2014-04-25
US9561287B2 (en) 2017-02-07
CA2843883A1 (en) 2013-02-21
CA2843883C (en) 2020-04-28
ZA201400977B (en) 2017-11-29
US10729778B2 (en) 2020-08-04
JP6092867B2 (ja) 2017-03-08
US20140296150A1 (en) 2014-10-02
MX349950B (es) 2017-08-22
CN103857413A (zh) 2014-06-11
AU2012296954A1 (en) 2014-02-20
IN2014CN00989A (OSRAM) 2015-04-10
US20190105400A1 (en) 2019-04-11
IL230712A0 (en) 2014-03-31
EP2741781A1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
HK1198359A1 (en) Carrier-linked treprostinil prodrugs
WO2012122340A8 (en) Soluble guanylate cyclase activators
HK1259250A1 (zh) 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
ZA201405101B (en) "new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them."
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
WO2012177481A3 (en) Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013057570A3 (en) Acrylic polymer formulations
WO2013055684A8 (en) Rasagiline citramide
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
HK1198442A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2010138598A3 (en) Lxr modulators
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2014078309A8 (en) Cannabinoid receptor mediating compounds
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
HK1214128A1 (zh) 癌症的治療
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
IL233055A (en) History of (1r, r4) 7 – oxo – 2 – azabicyclo [2.2.2] oct – 5 – ann
WO2013074871A3 (en) Humanin analogs
WO2012108631A3 (en) Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof
WO2009121946A3 (en) Process for the preparation of optically enriched clopidogrel
WO2013081563A3 (en) Stable voglibose tablet formulations
AP2012006149A0 (en) New dihydro-oxazolobenzodiazepinone compounds, a process for their preparation and pharmaceutical compositions containing them.